Clinical Trials

On the Horizon – Estrogen Receptor Modulator Reduces Bone Complications from Androgen Deprivation Therapy for Prostate Cancer

A multi-center Phase III study was discussed at the 2009 meeting of the American Urological Association.[1] The perliminar results of this study has demonstrated that the risk for incurring bone fractures in men on androgen deprivation therapy (ADT) is reduced when the drug toremifene (Acapodene) is administered. Men, fighting advanced prostate cancer, often receive long-term [...]

By Malecare|2017-10-19T10:54:32-04:00September 22nd, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Hormone Therapy, On The Horizon, Uncategorized|0 Comments

Patient Care Costs in Clinical Trials – A Problem

Clinical trials are the lifeblood of new drug and treatment development. Trials allow us to learn what developing drugs and treatment are both safe and effective. Many drug developers complain about their inability to attract enough volunteers to reach a sample size that will allow them to draw statistically valid conclusions. Everyday there are trials [...]

By Malecare|2021-02-17T10:55:23-05:00September 15th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Insurance, Research, Uncategorized|0 Comments

On the Horizon – Sunitinib Malate for Metastatic Castration-Resistant Prostate Cancer Following Docetaxel Chemotherapy

Docetaxel (Taxotere), or chemotherapy, will as all other treatments for advanced prostate cancer stop working. Many of us will progress quickly to this stage and eventually face a situation where there are no longer any approved treatments available to control our prostate cancer. If you are lucky enough to have an oncologist who is creative [...]

By Malecare|2017-10-19T10:54:37-04:00August 31st, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, End-Of-Life, On The Horizon, Uncategorized, Understanding APC|0 Comments

A Telephone Workshop on Metastatic Prostate Cancer

Cancer Care is conducting a telephone workshop on Metastatic Prostate Cancer on Tuesday, September 22, 2009 from 1:30 to 2:30 eastern time. Listening in on the workshop is free. Participants in the workshop will be: Susan Slovin MD, PhD, Associate Attending Physician, Genitourinary Oncology Service, Sidney Kimmel Center for the Treatment of Prostate & Urologic [...]

By Malecare|2020-02-04T10:10:57-05:00August 18th, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Metastases, Uncategorized, Understanding APC|0 Comments

Combining Radiopharmaceuticals and Bisphosphonates to Treat Bone Mets

A recent study of one man at the Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, The Netherlands combined both treatment modalities, radiopharmaceuticals and bisphosphonates, to combat bone pain caused by bone metastases. Their results were surprising. Bone-seeking radiopharmaceuticals and bisphosphonates are both an indicated treatment for men with prostate cancer when painful [...]

By Malecare|2017-10-19T10:54:41-04:00August 15th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, Metastases, On The Horizon, Uncategorized, Understanding APC|0 Comments

On the Horizon- Patupilone in Patients with Metastatic Castration-Resistant Prostate Cancer who have Progressed after Docetaxel – A Phase II Study

Once we have failed docetaxel therapy (chemo therapy) we have very few options available to control advanced prostate cancer. There is a recnt report about a clinical trial using a new potential drug, Patupilone. Patupilone has shown some evidence that it exhibits a limited positive effect in the pre-clinical setting in taxane resistant models of [...]

By Malecare|2017-10-19T10:54:41-04:00August 14th, 2009|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, Uncategorized, Understanding APC|0 Comments

Extending Survival of Prostate Cancer Survivors by Using Sodium Clodronate

In a small trial using oral sodium clodronate, a bisphosphonate like Zometa and Fosamax, it was shown to extended prostate cancer survival by 23 percent (23%). The survival benefit was seen only when the drug was used in combination with hormone therapy in men with metastatic disease. Many doctors have believed that bisphosphonates could have [...]

By Malecare|2017-10-19T10:54:42-04:00August 13th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Metastases, Research, Uncategorized, Understanding APC|0 Comments

Combined Androgen Blockade (ADT2) with Bicalutamide (Casodex) For Advanced Prostate Cancer Provides Increased Survival Time

One of the first treatments used when diagnosed with advanced or recurrent prostate cancer is hormone therapy. Hormone therapy (androgen blockade) is a systematic treatment, or it treats the cancer through the entire body. Prostate cancer that is believed to be in the gland is treated with a localized, focused treatment of the actual gland [...]

By Malecare|2017-10-19T10:54:44-04:00August 5th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

On the Horizon – Positive Efficacy Data From Phase I – II Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

Medivation, Inc. (MDVN) announced that its on-going clinical trial (phase I & II) of MDV3100 in castrate resistant prostate cancer has demonstrated both efficacy and safety in its current trials. The drug under study, MDV3100, is novel androgen receptor antagonist. This trial tracked 114 prostate cancer survivors who are hormone resistant (CRPC) for 12 weeks [...]

By Malecare|2017-10-19T10:54:44-04:00August 4th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, On The Horizon, Technology, Uncategorized|0 Comments

ADT2 Shows Survival Advantage Over ADT 1

Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]

By Malecare|2017-10-19T10:54:45-04:00July 28th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments